Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > CPH repurchased at C$1.14 and Employees bought at C$1.05

<< Previous

Bullboard Posts

Next >>

Comment by pabalooon Mar 05, 2021 2:47pm

133 Views

Post# 32730223

RE:RE:RE:CPH repurchased at C$1.14 and Employees bought at C$1.05

What hospital products are they referring too? These clowns are dreaming? I must have missed it in there last 10 conference calls and financials? They will be .50 cents soon. I might buy back in!

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant